Checkpoint Therapeutics Q1 EPS $(0.33) Misses $(0.27) Estimate
Portfolio Pulse from Benzinga Newsdesk
Checkpoint Therapeutics (NASDAQ:CKPT) reported Q1 losses of $(0.33) per share, missing the consensus estimate of $(0.27) by 22.22%. However, this represents a 62.92% improvement over the previous year's $(0.89) per share loss.
May 10, 2024 | 12:33 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Checkpoint Therapeutics reported a Q1 loss per share of $(0.33), missing estimates but improving year-over-year from $(0.89) loss.
While CKPT missed the consensus estimate for Q1 EPS, the significant improvement from the previous year's loss may mitigate negative investor sentiment. The miss could lead to short-term price pressure, but the year-over-year improvement is a positive sign that may balance out investor reactions.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100